Daily Temozolomide Following Failure of Prior RT + TMZ for GBM:

Update on the RESCUE Study

J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S. Kirby, D. MacDonald,

C. Shields and J.-F. Pouliot

42-year-old woman with GBM treated with daily temozolomide at first relapse on the NCIC-CTG/EORTC Trial

PD: 9 mo after RT/TMZ,6 cycles adjuvant TMZ

CR after 4 cycles continuous TMZ 50 mg/m2

Temozolomide Dose-intense Rescue

RESCUE Study Design

Study Objectives

Main Inclusion Criteria

Main Exclusion Criteria

Demographics

Six-month Progression-free Survival

Progression-free Survival (by subgroup)

Non hematological Toxicity (worst grade)

*All AEs irrespective of causality incidence >2%

No Grade 4 toxicity reported at this point in time

Hematological Toxicity(worsened grade since baseline)

Baseline Hematological Abnormalities(all patients)

Conclusions